Population-Based Genomic Screening: Recent Results & the Road Ahead


Geisinger

Adam Buchanan, MS, MPH, CGC

Co-Director, MyCode Genomic Screening & Counseling program

Director, Genomic Medicine Institute

Pennsylvania



"Geisinger is as close to Iceland as you'll find in the United States" - Glenn Steele, 2003

Attractive features for longitudinal, genomic medicine research and implementation:

- Large, stable population: >3 M people (>1 M active patients) with many 3+ generation families
- Strong and trusting relationship between patients and Geisinger
- Integrated healthcare delivery system
- Longstanding EHR and comprehensive clinical data
- Epic implementation from 1996 (2nd or 3rd customer)
- Innovative and supportive leadership
- MyCode® BioBank began in 2007
 Now MyCode® Community Health Initiative

DiscovEHR - Collaboration


- Since 2014, Regeneron Genetics Center has been our main scientific partner under MyCode Community Health Initiative
- RGC is subsidiary of Regeneron, a leading, science-focused biotechnology company
- Goals of "DiscovEHR" collaboration:
 - Map genetic variation across human genome
 - Advance understanding of human biology, discovering gene-disease connections, and identifying potential targets for new medicines
- Through DiscovEHR, Geisinger and RGC are creating one of world's most comprehensive genetics databases, matching genetic data to de-identified electronic health records of nearly 145,000 people so far

Genomic screening opportunity

- Reviewing exome data for actionable findings could improve identification of genetic risk
 - Clinically actionable genetic conditions are common (2-6%)
 - At least 1% of U.S. has 'CDC Tier 1' condition, but few are aware
 - Opportunity to mitigate risks for cancer and heart disease

Condition	Genes	Diseases	Lifetime Risks	Interventions
Familial hypercholesterolemia	LDLR, APOB, PCSK9	Early heart disease, stroke	Up to 50%	Lipid lowering therapy
Hereditary breast & ovarian cancer syndrome	BRCA1, BRCA2	Breast, ovarian, prostate & other cancers	Up to 70%	Surveillance, prophylactic surgery
Lynch syndrome	MLH1, MSH2, MSH6, PMS2	Colon, uterine & other cancers	Up to 70%	Surveillance, prophylactic surgery

Green RC et al., 2013, Genet Med; Dorschner MO et al., 2013, AJHG; Retterer K et al., 2015; Genet Med; https://www.ncbi.nlm.nih.gov/books/NBK1116/; Kuchenbaecker KB et al., 2017, JAMA; Manickam K et al., 2018, JAMA Netw Open; Abul-Husn NS et al., 2016, Science; Win AK et al., 2017, CEBP; Austin MA et al., 2004, Am J Epidemiol; Hampel H et al., 2011, Cancer Prev Res; Nordestgaard BG et al., 2013, Eur Heart J; King MC, 2014, JAMAs



https://www.geisinger.org/-/media/OneGeisinger/pdfs/ghs/research/mycode/mycode-scorecard.pdf?la=en

MyCode Genomic Screening and Counseling (GSC) Program



 MyCode patient-participants and their families are empowered to act on genomic information and prevent disease



 Implement an innovative, scalable clinical program that supports patients, their families and healthcare professionals in the routine integration of genomic results into care

MyCode GSC Program Principles: SCREENING

Reach broad expert consensus on which genes to evaluate & return	Determined by multiple stakeholders & reviewed regularly	
Return only pathogenic/likely pathogenic variants in clinically actionable genes		
Minimize false positives (specificity > sensitivity)	Only want to call "slam-dunk" positives	
Supportive infrastructure for patients & clinicians		

Results disclosure



Primary care provider notified of a patient's result

- Electronic health record communication
- Option for PCP to disclose



Genetic counselor discloses result by phone

- Often unanticipated call
- May not be related to acute concerns



Brief description of risk and specific gene

- Gene causes risk for, e.g., heart disease, early cancer
- Screening and prevention may include...



Recommend discussion with genetic counselor

- Service provided at no charge
- Refer to other appropriate healthcare providers



Recommend discussing result with family members

• Program provides letters and resources to help with this communication

CDC 'Tier 1' Conditions Disclosed

MyCode® results re 1612 patient-participants have recent from the Genomic Screening and Control of the latest results, see geisinger.org/Market for the latest results, see geisinger.	1	September 1, 2020	
Risk Condition	Patients per risk condition	Gene	Patients per gene
CDC t	ier 1 conditions (clic	k link)	
Hereditary breast and ovarian cancer (early breast, ovarian, prostate and other cancers)	413	BRCA1 BRCA2	141 272
Familial hypercholesterolemia (early heart attacks and strokes)	157	APOB LDLR	36 121
Lynch syndrome (early colon, uterine and other cancers)	198 198	PMS2 MSH6 MSH2 MLH1	84 86 15 13
Totals	1621	• • • •	1621

Priority Research Questions

- Overall goal Measure population health impact of our program by evaluating:
 - Penetrance of actionable variants in unselected population
 - Family communication and cascade testing interventions
 - Adherence to risk management recommendations
 - Digital scaling tools (e.g., chatbots)
 - Novel genomic counseling models
 - Risk-benefit balance of genomic screening

 Multi-disciplinary, mixed methods approaches to addressing questions



Original Investigation | Genetics and Genomics


Exome Sequencing-Based Screening for *BRCA1/2* Expected Pathogenic Variants Among Adult Biobank Participants

Kandamurugu Manickam, MD, MPH; Adam H. Buchanan, MS, MPH; Marci L. B. Schwartz, ScM; Miranda L. G. Hallquist, MSc; Janet L. Williams, MS; Alanna Kulchak Rahm, PhD, MS; Heather Rocha, MS; Juliann M. Savatt, MS; Alyson E. Evans, BS; Loren M. Butry, MS; Amanda L. Lazzeri, BS; D'Andra M. Lindbuchler, MSN; Carroll N. Flansburg, MPH; Rosemary Leeming, MD, MHCM; Victor G. Vogel, MD, MHS; Matthew S. Lebo, PhD; Heather M. Mason-Suares, PhD; Derick C. Hoskinson, PhD; Noura S. Abul-Husn, MD, PhD; Frederick E. Dewey, MD; John D. Overton, PhD; Jeffrey G. Reid, PhD; Aris Baras, MD; Huntington F. Willard, PhD; Cara Z. McCormick, MPH; Sarath B. Krishnamurthy, PhD; Dustin N. Hartzel, BS; Korey A. Kost, BS; Daniel R. Lavage, BS; Amy C. Sturm, MS; Lauren R. Frisbie, BS; T. Nate Person, MS; Raghu P. Metpally, PhD; Monica A. Giovanni, MS; Lacy E. Lowry, MD; Joseph B. Leader, BA; Marylyn D. Ritchie, PhD; David J. Carey, PhD; Anne E. Justice, PhD; H. Lester Kirchner, PhD; W. Andrew Faucett, MS; Marc S. Williams, MD; David H. Ledbetter, PhD; Michael F. Murray, MD

- Identify pathogenic & likely pathogenic (P/LP) BRCA1/2 variants in unselected research cohort
- Characterize features associated with P/LP variants

Key points

- 36% BRCA1 (n=95)
 64% BRCA2 (n=172)
- Prevalence: 1:180 (corrected for relatedness)
- Only 18% had prior clinical BRCA testing
- ~50% of those without prior testing did not meet NCCN genetic testing criteria
- BRCA-associated cancers more common in cases vs. controls



ARTICLE Genetics





Clinical outcomes of a genomic screening program for actionable genetic conditions

Adam H. Buchanan, MS, MPH[®]¹, H. Lester Kirchner, PhD², Marci L. B. Schwartz, ScM¹, Melissa A. Kelly, MS¹, Tara Schmidlen, MS¹, Laney K. Jones, PharmD, MPH¹, Miranda L. G. Hallquist, MSc¹, Heather Rocha, MS¹, Megan Betts, MS¹, Rachel Schwiter, MS¹, Loren Butry, MS¹, Amanda L. Lazzeri, BS¹, Lauren R. Frisbie, BS¹, Alanna Kulchak Rahm, PhD, MS¹, Jing Hao, PhD, MD^{1,2}, Huntington F. Willard, PhD^{1,3}, Christa L. Martin, PhD^{1,4}, David H. Ledbetter, PhD^{1,4}, Marc S. Williams, MD¹ and Amy C. Sturm, MS¹


What is <u>clinical utility</u> of genomic screening program among MyCode patients with a 'CDC Tier 1' genomic condition?

- Focus on patients for whom result is new information
 - Personal/family history of relevant disease prior to disclosure
 - Risk management procedure(s) post-disclosure
 - Relevant diagnosis post-disclosure
- Double-coded chart review performed by GCs, OB-GYN resident in June-Dec 2018
 - Median follow-up window: 21.8 months (inter-quartile range 15-31 months)

Characteristics	FH (<i>n</i> =93)	HBOC (<i>n</i> =202)	Lynch (<i>n</i> =56)	All study participants (<i>n</i> =351 ^a)
Female sex	56 (60.2%)	103 (51.0%)	32 (57.1%)	191 (54.4%)
Race: White	92 (98.9%)	291 (99.5%)	56 (100%)	349 (99.4%)
Race: African American	1 (1.1%)	1 (0.5%)	-	2 (0.6%)
Race: Other	-	-	-	-
Ethnicity: Non-Hispanic/ Non-Latino	92 (98.9%)	199 (98.5%)	56 (100%)	348 (99.2%)
Ethnicity: Other/ Hispanic/ Latino	1 (1.1%)	3 (1.5%)	-	3 (0.8%)
Current smoker	13 (14%)	43 (21.3%)	11 (19.6%)	67 (19,1%)
Alive at initial data pull	93 (100%)	194 (96.0%)	56 (100%)	343 (97.7%)
Median age in years (IQR)	62.7 (51.2, 72.0)	62.6 (50.6-72.1)	62.8 (53.8-73.8)	62.7 (51.0-72.2)
Median Charlson comobility Index (IQR)	5 (1-7)	4 (2-6)	4 (2-6.5)	4 (2-6)
Median follow-up in months (IQR, range) ^b	14.4 (12.8- 30.5,7.4-43.3)	24,2 (21.1- 32.8,0.6-43.3)	14.7 (12.6=28.9, 8.0- 36.3)	21.8 (14.5-30.6, 0.6-43.3)
Prior genetic diagnosis	0/93 (0%)	39/202 (19.3%)	7/56 (12.5%)	46/351 (13.1%)

Relevant personal & family history

- Among 305 w/o prior molecular diagnosis
- 65% had relevant personal and/or family history
- Significant differences by genetic condition



■ FH (n=93) ■ HBOC (n=163) ■ Lynch (n=49)

Risk management

- 70% of eligible patients had post-disclosure risk management
- Factors associated with risk management:
 - Post-disclosure genetic counseling
 - Genetic condition
 - Prior risk management

	FH (<i>n</i> =93)	HBOC (<i>n</i> =163)	Lynch (<i>n</i> =49)	All (<i>n</i> =305)
Risk management	93/93	114/163	48/49	255/305
eligible ^a	(100%)	(69.9%)	(98.0%)	(83.6%)
Risk management predisclosure ^b	69/93	43/114	11/48	123/255
	(74.2%)	(37.7%)	(22.9%)	(48.2%)
Risk management postdisclosure ^c	78/93	82/114	19/48	179/255
	(83.9%)	(71.9%)	(39.5%)	(70.2%)
New diagnosis	26/93	10/163	5/49	41/305
postdisclosure ^d	(28.0%)	(6.1%)	(10.2%)	(13.4%)

Post-disclosure diagnoses

- 13% (41/305) had post-disclosure diagnosis
 - 25 of these (61%) had EHR documentation of diagnosis being precipitated by genomic results disclosure

FH (n=26)	HBOC (n=10)*	Lynch (n=5)
LDL-C >190 mg/dL (20)	Breast cancer (4)	Colon adenoma (4)
Atherosclerosis (5)	Prostate cancer (3)	Sebaceous adenoma (1)
Claudication/peripheral vascular disease (4)	Fallopian tube cancer (1)	
Corneal arcus (4)	STIC lesion (1)	
Xanthoma or xanthelasma (3)	Ampulla of Vater cancer (1)	
Cerebrovascular accident (2)		

*All tumors stage IIA or earlier

STIC = serous tubal intraepithelial carcinoma

Priority Research Questions con.

• What have we learned so far?

- Actionable genetic conditions are more common than previously thought
- Genomic screening identifies at-risk individuals more comprehensively than clinical ascertainment
- Majority of patients use genetic result to guide care
- Genomic screening can lead to early cancer diagnoses

• What's left?

- Penetrance in diverse unselected populations
- Longer-term health outcomes
- Cost (financial, psychological, healthcare system)

eBox. Twelve Questions to Be Addressed in Pilot Studies of Large-Scale DNA-Based Screening

- 1. How should screening be designed to offer inclusive benefits for the whole population (with specific attention to the poor, as well as underrepresented racial and ethnic groups)?
- 2. What are the appropriate population characteristics for screening (eg, age, sex)?
- 3. What is the optimal testing strategy/technology (eg, exome sequencing, multigene panel, single-nucleotide polymorphism array)?
- 4. What are the ideal lead institutions for carrying out DNA-based screening (eg, health care provider organizations, departments of public health, for-profit companies)?
- 5. How should DNA-based screening (primary screen) be paid for (eg, government funding, private insurance, self-pay)?
- 6. How should clinical follow-up (secondary screen) be paid for (eg, government funding, private insurance, self-pay)?
- 7. How often should data be reanalyzed (eg, compared with evolving databases like ClinVar [updated anually])?
- 8. What strategy should be pursued for cascade testing (eg, should at-risk family members be automatically contacted by health system)?
- 9. What are the short-term clinical outcomes (eg, correcting diagnostic misattribution, presymptomatic diagnosis of cancer or heart disease)?
- 10. What are the long-term clinical outcomes (eg, nonpenetrance, overdiagnosis)?
- 11. What are the best practices regarding negative screening result reporting (critically important to avoid false reassurance)?
- 12. What are the clinical workforce needs related to delivering DNA-based results and clinical follow-up at population scale (ie, how many medical geneticists, genetic counselors, specialists, others)?

Acknowledgements

mycode

Thank you to:

Our MyCode patient-participants, Geisinger Providers and Staff, and the MyCode Research Team

Geisinger MyCode Executive Committee

David H. Ledbetter, PhD Christa Lese Martin, PhD Amy Sturm, MS Adam Buchanan, MS, MPH Daniel Davis, PhD David Rolston, MD

Regeneron Genetics Center

Aris Baras, MD, PhD Jeff Reid, PhD John Overton, PhD

Funding from:

Geisinger Regeneron Pharmaceuticals

Genomic Screening & Counseling program:

Amy Sturm, MS Adam Buchanan, MS, MPH Marc Williams, MD Cara McCormick, MPH Amanda Lazzeri, BS Gary Bellus, MD Laney Jones, MPH, PharmD Alanna Kulchak Rahm, PhD, MS Marci Schwartz, ScM Heather Rocha, MS Tara Schmidlen, MS Miranda Hallquist, MSc Megan Betts, MS Rachel Schwiter, MGC Nicole Deckard, MS Gretchen Thone, MS Kerrianne Fry, MS Missie Kelly, MS Tasha Strande, PhD Alyson Evans, MS Eric Tricou, MS Krista Zimmerman, BS Amie Decker, BS